HACI AHMET BİRCAN, MÜNİRE ÇAKIR, İLKAY YILMAZER KAPULU, RECEP SÜTCÜ, SELÇUK KAYA, ÖNDER ÖZTÜRK

Elevated serum matrix metalloproteinase-2 and -9 and their correlationswith severity of disease in patients with community-acquired pneumonia

Background/aim: To determine the role of matrix metalloproteinases (MMPs) and their relationship with the clinical course of community-acquired pneumonia (CAP). Materials and methods: Sixty-two consecutively hospitalized patients with CAP were enrolled and their pneumonia severity index (PSI), time to clinical stability (TCS), treatment response, and complications were recorded. The pre- and posttreatment serum concentrations of MMPs and their inhibitors were analyzed by ELISA. The activities of MMPs were evaluated by gelatin zymography. Results: MMP-2 and -9 serum levels and their activities were higher in CAP patients than controls (P < 0.001 and P < 0.001, respectively). Low-risk patients had lower levels of MMP-2 and TIMP-1 than high-risk patients (P = 0.044, P = 0.001, respectively). Pretreatment serum TIMP-1 level was higher in patients with TCS of >3 days (P = 0.004) and was correlated with oxygenation and PSI scores. Posttreatment serum levels of MMP-9 and TIMP-1 were decreased after antibiotics (P = 0.0001 and P = 0.017, respectively). Conclusion: Although MMP-2, MMP-9, and TIMP-1 correlate with many poor prognostic factors, more studies are required to prove their possible role in predicting the severity of CAP.

Anahtar Kelimeler:

Matrix metalloproteinases, matrix metalloproteinase inhibitors, pneumonia, severity of illness index

Elevated serum matrix metalloproteinase-2 and -9 and their correlationswith severity of disease in patients with community-acquired pneumonia

Keywords:

Matrix metalloproteinases, matrix metalloproteinase inhibitors, pneumonia, severity of illness index,

PDF

___

File TM Jr. Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. Am J Med 2004; 117 (Suppl. 3A): 39S–50S.
Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults. Incidence, etiology, and impact. Am J Med 1985; 78: 32–37.
Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA et al. Guidelines for the management of adults with community- acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730–1754.
Dehoux MS, Boutten A, Ostinelli J, Seta N, Dombret MC, Crestani B, Deschenes M, Trouillet JL, Aubier M. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1994; 150: 710–716.
Busund R, Lindsetmo RO, Rasmussen LT, Rokke O, Rekvig OP, Revhaug A. Tumor necrosis factor and interleukin 1 appearance in experimental gram-negative septic shock. The effects of plasma exchange with albumin and plasma infusion. Arch Surg 1991; 126: 591–597.
Yang SF, Chu SC, Chiang IC, Kuo WF, Chiou HL, Chou FP, Kuo WH, Hsieh YS. Excessive matrix metalloproteinase-9 in the plasma of community-acquired pneumonia. Clin Chim Acta 2005; 352: 209–215.
Parks WC, Shapiro SD. Matrix metalloproteinases in lung biology. Respir Res 2001: 10–19.
Caughey GH. Serine proteinases of mast cell and leukocyte granules: a league of their own. Am J Respir Crit Care Med 1994; 150: S138–S142. 9. Shapiro SD. Elastolytic metalloproteinases produced by human mononuclear phagocytes: potential roles in destructive lung disease. Am J Respir Crit Care Med 1994; 150: S160–S164.
Delclaux C, Delacourt C, D’Ortho MP, Boyer V, Lafuma C, Harf A. Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Am J Respir Cell Mol Biol 1996; 14: 288–295.
Mautino G, Oliver N, Chanez P, Bousquet J, Capony F. Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics. Am J Respir Cell Mol Biol 1997; 17: 583–591.
Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115: 3719–3727.
Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003; 253: 269–285.
Vernooy JH, Lindeman JH, Jacobs JA, Hanemaaijer R, Wouters EF. Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 2004; 126: 1802–1810.
Cataldo D, Munaut C, Noel A, Frankenne F, Bartsch P, Foidart JM, Louis R. Matrix metalloproteinases and TIMP- 1 production by peripheral blood granulocytes from COPD patients and asthmatics. Allergy 2001; 56: 145–151.
Roderfeld M, Rath T, Schulz R, Seeger W, Tschuschner A, Graf J, Roeb E. Serum matrix metalloproteinases in adult CF patients: relation to pulmonary exacerbation. J Cyst Fibros 2009; 8: 338–347.
Karakoc GB, Inal A, Yilmaz M, Altintas DU, Kendirli SG. Exhaled breath condensate MMP-9 levels in children with bronchiectasis. Pediatr Pulmonol 2009; 44: 1010–1016.
Sepper R, Konttinen YT, Buo L, Eklund KK, Lauhio A, Sorsa T, Tschesche H, Aasen AO, Sillastu H. Potentiative effects of neutral proteinases in an inflamed lung: relationship of neutrophil procollagenase (proMMP-8) to plasmin, cathepsin G and tryptase in bronchiectasis in vivo. Eur Respir J 1997; 10: 2788–2793.
Jin Q, Huang FH, Zhou Y, Zhang YQ, Chai XJ. Effect of pseudomonas aeruginosa on the expressions of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in the airway of bronchiectasis patients. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2012; 34: 384–389.
Corbel M, Belleguic C, Boichot E, Lagente V. Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway inflammation and pulmonary fibrosis. Cell Biol Toxicol 2002; 18: 51–61.
Lanchou J, Corbel M, Tanguy M, Germain N, Boichot E, Theret N, Clement B, Lagente V, Malledant Y. Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients. Crit Care Med 2003; 31: 536–542.
Wilkinson TS, Morris AC, Kefala K, O’Kane CM, Moore NR, Booth NA, McAuley DF, Dhaliwal K, Walsh TS, Haslett C et al. Ventilator-associated pneumonia is characterized by excessive release of neutrophil proteases in the lung. Chest 2012; 142: 1425–1432.
Schaaf B, Liebau C, Kurowski V, Droemann D, Dalhoff K. Hospital-acquired pneumonia with high-risk bacteria is associated with increased pulmonary matrix metalloproteinase activity. BMC Pulm Med 2008; 8: 12.
Hartog CM, Wermelt JA, Sommerfeld CO, Eichler W, Dalhoff K, Braun J. Pulmonary matrix metalloproteinase excess in hospital-acquired pneumonia. Am J Respir Crit Care Med 2003; 167: 593–598.
El-Solh AA, Amsterdam D, Alhajhusain A, Akinnusi ME, Saliba RG, Lynch SV, Wiener-Kronish JP. Matrix metalloproteases in bronchoalveolar lavage fluid of patients with type III Pseudomonas aeruginosa pneumonia. J Infect 2009; 59: 49–55.
Chiang TY, Shyu LY, Tsao TC, Chien MH, Tsao SM, Lee YT, Yang SF. Elevated plasma matrix metalloproteinase-9 protein and its gene polymorphism in patients with community- acquired pneumonia. Clin Chem Lab Med 2012; 50: 449–454.
Chiang TY, Yu YL, Lin CW, Tsao SM, Yang SF, Yeh CB. The circulating level of MMP-9 and its ratio to TIMP-1 as a predictor of severity in patients with community-acquired pneumonia. Clin Chim Acta 2013; 424: 261–266.
Puljiz I, Markotić A, Cvetko Krajinovic L, Gužvinec M, Polašek O, Kuzman I. Mycoplasma pneumoniae in adult community- acquired pneumonia increases matrix metalloproteinase-9 serum level and induces its gene expression in peripheral blood mononuclear cells. Med Sci Monit 2012; 18: CR500–505.
Özlü T, Bülbül Y, Alataş F, Arseven O, Coşkun AS, Çilli A, Ekim N, Erdem H, Gürsel G, Hatipoğlu ON et al. Turk Toraks Dernegi eriskinlerde toplumda gelisen pnomoni tani ve tedavi uzlasi raporu. Turkish Thoracic Journal 2009; 10 (Suppl. 9): 1–16 (in Turkish).
Bircan A, Sütçü R, Gökırmak M, Hiçyılmaz H, Akkaya A, Öztürk Ö. Total antioxidant capacity and C-reactive protein levels in patients with community-acquired pneumonia. Turk J Med Sci 2008; 38: 537–544.
Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243–250.
Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS, Singer DE. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279: 1452–1457.
Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. 2001 SCCM/ ESICM/ACCP/ATS/SIS International sepsis definitions conference. Crit Care Med 2003; 31: 1250–1256.
Leber TM, Balkwill FR. Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. Anal Biochem 1997; 249: 24–28.
Pugin J. Clinical signs and scores for the diagnosis of ventilator- associated pneumonia. Minerva Anestesiol 2002; 68: 261–265.
Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic “blind” bronchoalveolar lavage fluid. Am Rev Respir Dis 1991; 143: 1121–1129.